Funds and ETFs Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:54 2024-04-19 am EDT 5-day change 1st Jan Change
866.2 DKK +0.41% Intraday chart for Novo Nordisk A/S -1.57% +24.08%

ETFs positioned on Novo Nordisk A/S

Name Weight AuM 1st Jan change Investor Rating
21.31% 192 M€ +11.13%
10.45% 5 M€ +4.22%
5.40% 18 M€ +1.40% -
4.67% 88 M€ +10.37% -
3.95% 4 M€ -.--% -
3.91% 5 M€ +10.09% -
3.91% 14 M€ +5.66% -
3.78% 6 M€ -.--%
3.09% 12 M€ +15.09% -
3.02% 6 M€ -.--% -
2.87% 29 M€ +8.37% -
2.53% 3,859 M€ +18.82% -
2.53% 469 M€ -2.05% -
2.22% 3 M€ +9.95% -
1.91% 2 M€ -.--% -
1.91% 2 M€ +9.19% -
1.67% 10 M€ -3.35% -
1.60% 10 M€ +6.14% -
1.31% 267 M€ +5.34%
1.30% 49 M€ +3.53%
1.04% 276 M€ +11.40% -
1.03% 7 M€ -0.18% -
0.89% 1,120 M€ -1.50%
0.79% 284 M€ -.--%
0.76% 786 M€ -.--%
0.76% 23 M€ -.--% -
0.75% 206 M€ -.--%
0.70% 7 M€ +0.11% -
0.64% 277 M€ -.--% -
0.64% 194 M€ +4.96% -
0.64% 441 M€ +7.19%
0.57% 717 M€ +4.39%
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
866.2 DKK
Average target price
904.2 DKK
Spread / Average Target
+4.39%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. Funds and ETFs Novo Nordisk A/S